Biorestorative Therapies (BRTX)
(Delayed Data from NSDQ)
$1.69 USD
+0.19 (12.67%)
Updated Sep 13, 2024 03:55 PM ET
After-Market: $1.67 -0.02 (-1.18%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
BRTX 1.69 +0.19(12.67%)
Will BRTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BRTX
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates
BRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Top Estimates
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates
Other News for BRTX
Buy Rating Affirmed for BioRestorative Therapies Amid Strong Financials and Clinical Progress
BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript
BioRestorative Therapies Clarifies Press Release Usage in Filings
BRTX Stock Earnings: BioRestorative Therapies Beats EPS, Beats Revenue for Q2 2024